Article: Alk-Abello's Grazax for children launched in UK.(Brief article)

Danish firm ALK-Abello's Grazax, a tablet-based immunotherapy product for grass pollen allergy, is now available for use in children and adolescents aged five to 17 in the UK.

Grazax is the only non-injection immunotherapy licensed to treat children suffering from severe grass pollen-induced seasonal allergic rhinitis and conjunctivitis or severe hay fever. In addition, it is the first immunotherapy tablet to address the underlying cause of grass pollen allergy. It is a once-daily, fast-melting tablet which is placed under the tongue. Grazax has been available ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!